Appendix 7—table 2. Estimates from models of the rate of decline in viremia and clinical outcomes.

	Severe dengue		Plasma leakage
	OR (95% CI)	p	OR (95% CI)	p
Rate of decline in viremia (per 0.5 log-10 copies/ml increase)	0.14 (0.06; 0.33)	<0.001		<0.001
- DENV-1 – probable primary			0.23 (0.09; 0.56)
- DENV-1 – probable secondary			0.12 (0.05; 0.28)
- DENV-2 – probable primary			0.30 (0.11; 0.80)
- DENV-2 – probable secondary			0.16 (0.06; 0.38)
- DENV-3 – probable primary			0.18 (0.06; 0.54)
- DENV-3 – probable secondary			0.09 (0.03; 0.27)
- DENV-4 – probable primary			0.78 (0.24; 2.50)
- DENV-4 – probable secondary			0.40 (0.16; 1.04)
Serotype		0.001		0.006
- DENV-1	Ref		Ref
- DENV-2	0.74 (0.39; 1.39)		1.04 (0.75; 1.45)
- DENV-3	0.21 (0.05; 0.88)		0.81 (0.54; 1.22)
- DENV-4	8.59 (2.38; 31.03)		4.84 (2.07; 11.32)
Immune status		<0.001		<0.001
- Probable primary	Ref		Ref
- Probable secondary	63.23 (8.15; 490.31)		2.77 (1.78; 4.33)
- Indeterminate	16.29 (1.77; 150.25)		1.39 (0.68; 2.82)
PCR method		<0.001		<0.001
- One-step	Ref		Ref
- Two-step	33.32 (10.92; 101.66)		14.62 (6.98; 30.60)
Interaction of rate of decline in viremia
- With serotype				0.182
- With immune status				0.017
- With PCR				0.006

The model for severe dengue does not include any interaction term.

In the model of plasma leakage, interactions between the rate of decline in viremia and serotype, immune status, and PCR are included. ORs and 95% CIs of the rate of decline in viremia are estimated for the one-step PCR in each subgroup of serotype and probable primary/secondary infection. ORs and 95% CIs of serotype, immune status, and PCR are estimated for the rate of decline in viremia of 1.4 log-10 copies/ml.

CI, confidence interval; DENV, dengue virus; OR, odds ratio; PCR, polymerase chain reaction; Ref, reference.